

## THIS ISSUE'S AUTHORS

**LINDA A. DIMEFFE, PH.D.**, is a chief scientific officer at Behavioral Tech Research, Inc., a research organization dedicated to the dissemination of evidence-based practices (EBPs). She is also a clinical instructor in the Department of Psychology at the University of Washington. Her research interests include EBPs, addictive behaviors, dialectical behavior therapy (DBT), and the adaptation of DBT for substance-dependent individuals with borderline personality disorder. She has received four technology transfer grants from NIDA to disseminate DBT. Dr. Dimeff is the primary editor of *Dialectical Behavior Therapy in Clinical Practice: Applications Across Disorders and Settings* (2007).

**KYLE M. KAMPMAN, M.D.**, is a board-certified psychiatrist specializing in addiction psychiatry. He is currently the medical director of the Charles O'Brien Center for the Treatment of Addictions, and an associate professor of psychiatry and the medical director of the University of Pennsylvania Treatment Research Center in Philadelphia. His research interests include pharmacotherapy for cocaine dependence and the cocaine withdrawal syndrome. He is currently engaged in a study of topiramate as a treatment for comorbid alcohol and cocaine dependence. He also serves on the editorial board of the *Journal of Addiction Medicine*.

**KENNETH L. KIRSH, PH.D.**, is an assistant professor in the Department of Pharmacy Practice and Science at the University of Kentucky and a licensed clinical psychologist. He has authored publications on the assessment and management of pain, the relationship of pain to abuse and addiction, and symptom management in cancer populations. He chairs the Hospice of the Bluegrass Research Committee and the Pain Treatment Center of the Bluegrass Pain Committee.

**MARSHA M. LINEHAN, PH.D.**, is a professor of psychology at the University of Washington; the founder of both the Marie Institute of Behavioral Technology and Behavioral Tech, LLC, a treatment dissemination company; and director of the Behavioral Research and Therapy Clinics. Her research involves applying behavioral models to the treatment of suicidality, drug abuse, and borderline personality disorder, as well as finding ways to transfer effective treatment methods from the academic to the clinical community. She is the author of numerous research articles, books, and treatment manuals.

**STEVEN D. PASSIK, PH.D.**, is an associate attending psychologist in the Department of Psychiatry and Behavioral Sciences at the Memorial Sloan-Kettering Cancer Center. He has treated people with cancer for nearly 20 years, and his work has focused on the psychological aspects of cancer, including palliative care, symptom management, pain, depression, nausea, and fatigue. He has written and published extensively on the interface of pain management and addiction.

**SEDDON R. SAVAGE, M.D., M.S.**, is a clinician, educator, and policy consultant in the fields of addiction and pain medicine; an associate professor of anesthesiology at the Dartmouth Medical School; and the director of the Dartmouth Center on Addiction Recovery and Education. She has held a number of national leadership positions in the fields of addiction and pain medicine, and is currently president of the New Hampshire Medical Society. She has published numerous journal articles and book sections, as well as a textbook on addiction medicine.

## &amp; PANEL RESPONDENTS

**MICHAEL P. BOGENSCHUTZ, M.D.**, is a professor of psychiatry and the vice-chair

for addiction psychiatry at the University of New Mexico Health Sciences Center and Center on Alcoholism, Substance Abuse, and Addictions in Albuquerque, New Mexico. He also directs the Addiction Psychiatry Fellowship Program in the Department of Psychiatry. Dr. Bogenschutz heads a program of clinical research in addiction treatment that includes federally funded studies of novel pharmacological and behavioral therapies for drug and alcohol addiction and co-occurring disorders. He is the principal investigator of the Southwest Node of the NIDA Clinical Trials Network.

**LAWRENCE J. DeMARZO** is the executive director of House of the Crossroads in Pittsburgh, Pennsylvania. House of the Crossroads employs a community-based and -oriented collaborative approach to drug abuse treatment service delivery, using the Therapeutic Community Model, and provides a comprehensive continuum of care. Mr. DeMarzo serves as the community treatment provider representative for the Appalachian Tri-State Node of the NIDA Clinical Trials Network. He has extensive experience with development, implementation, and collaboration of human services in community-based settings.

**MARDELL GAVRIEL, PSY.D.**, is the managing director of mental health at Walden House, a behavioral health agency providing integrated substance abuse and mental health treatment to underserved populations in California. Dr. Gavriel is a licensed psychologist who came to Walden House after earning a doctorate in clinical psychology from the Chicago School of Professional Psychology in 1997. She has developed and directed clinical programs at Walden House for the past 10 years and has implemented evidence-based practices in residential and outpatient settings. Her areas of specialization include dual diagnosis, cultural competency, and clinical skills.

**SUZETTE GLASNER-EDWARDS, PH.D.**, is a licensed clinical psychologist and assistant research psychologist at the University of California, Los Angeles Integrated Substance Abuse Programs. Her research interests include intervention development for substance abusers with and without co-occurring disorders. Currently, she is the principal investigator of a NIDA-funded psychosocial clinical trial of integrated cognitive-behavioral and motivational treatment strategies for stimulant users with co-occurring affective disorders. She is also examining pharmacological treatment approaches for this population.

**DENNIS PAUL, PH.D.**, received his doctorate in biopsychology from the University of British Columbia and postdoctoral training in the Department of Neurology at the Memorial Sloan-Kettering Cancer Center in New York. He has been a faculty member of the Department of Pharmacology at the Louisiana State University Health Sciences Center in New Orleans since 1990. His research interests include opioid receptor mechanisms in analgesia and drug abuse, and the development of novel drug therapies for neuropathic pain.

**JOHN ROLL, PH.D.**, is the director of the Washington Institute for Mental Health Research and Training at Washington State University. He is a vice-chair of the Washington State Governor's Council on Substance Abuse, where he is in charge of the treatment subcommittee. Dr. Roll's primary research interests are basic behavioral pharmacology and the development of behavioral interventions for substance abuse and related disorders. He has published numerous articles, abstracts, and book chapters.

**HELEN SACKLER, PH.D.**, is a licensed clinical psychologist. She is a clinical instructor in the Department of Psychiatry at Yale University Medical School and serves as a clinical supervisor for pre- and postdoctoral psychology interns. She is also a consultant and clinical supervisor at the APT Foundation, a substance abuse treatment agency. She has a private substance abuse treatment practice in New Haven, Connecticut.

**MARIA A. SULLIVAN, M.D., PH.D.**, is an associate professor of clinical psychiatry in the Division on Substance Abuse at the New York State Psychiatric Institute and Columbia University College of Physicians

and Surgeons. Her research interests include developing pharmacological and behavioral treatments for nicotine and opioid dependence, as well as for opioid abuse in individuals with chronic pain. She has published extensively on naltrexone and buprenorphine as treatments for opioid dependence, behavioral therapy for addiction, smoking cessation, the links between depression and addiction, and prescription opioid abuse.

**ROGER D. WEISS, M.D.**, is a professor of psychiatry at Harvard Medical School and clinical director of the Alcohol and Drug Abuse Treatment Program at McLean Hospital. He has been the principal investigator on numerous grants from NIDA and the National Institute on Alcohol Abuse and Alcoholism, and is currently principal investigator of the Northern New England Node of the NIDA Clinical Trials Network, where he is leading a multisite national trial on the treatment of prescription opioid dependence. He has authored numerous articles and book chapters, and has recently developed a new group therapy for patients with bipolar disorder and substance dependence.